TITLE:
A Study in Adult and Pediatric Patients With Cystic Fibrosis

CONDITION:
Cystic Fibrosis

INTERVENTION:
denufosol tetrasodium (INS37217) Inhalation Solution

SUMMARY:

      The purpose of this ascending dose group study is to assess the safety, tolerability, and
      effects of multiple dose levels of INS37217 and placebo followed by five days twice daily
      treatment with maximum tolerated dose administered by inhalation via the Pari LC Star
      nebulizer in adult and pediatric patients with cystic fibrosis
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 5 Years to N/A
Criteria:

        Inclusion Criteria:

          -  FEV1 40-70% (adults)

          -  FEV1 >/=50% (pediatrics)

          -  oxygen saturation >90%

          -  clinically stable

          -  willing to stay overnight

        Exclusion Criteria:

          -  abnormal renal or liver function

          -  receiving corticosteroids exceeding 10mg/day or 20 mg every other day

          -  received intravenous or aerosolized antibiotics 1 week prior to dosing
      
